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RESULTS
This search yielded thirty-eight articles for review, including case reports, prospective 
and retrospective studies, and prior literature reviews. The parameters reported included 
EKG changes, BNP and troponin elevations over time, pulmonary artery catheter 
pressures, echocardiographic findings, and their relation to morbidity and mortality. 
These publications and their key findings were summarized in a collected table. Their 
results and findings are compared within related measured outcomes. Of the articles, 12 
of the 38 focused on the relation between cardiac biomarkers, morbidity, and mortality. 
Of the 12, 10 articles showed elevated cardiac biomarkers to correlate with increased 
morbidity and mortality
 CONCLUSION
The relevance of elevated cardiac biomarkers 
following an aneurysmal SAH impact on 
morbidity and mortality is an under-researched 
topic, and warrants further investigation and 
development of standardized guidelines. A trend 
exists between the amount of cardiac biomarker 
elevation and poor outcomes, however there 
exist no guidelines aimed at monitoring and 
managing cardiac complications. 
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     INTRODUCTION
The incidence of subarachnoid hemorrhage (SAH) is approximately 2 
to 22 per 100,000, with incidence being about twice as high in women 
than men [1]. Neurogenic cardiomyopathy has become a well known 
sequelae of SAH, occurring in approximately 20-40% of patients 
[2,4,6,7]. It is generally believed that sympathetic stimulation of the 
myocardium causes contraction band necrosis leading to the 
cardiomyopathy. ECG changes observable in 50-100% of patients, and 
detectable cardiac troponins observed in 20-40% of patients [2,4,6,7]. 
Left ventricle wall motion abnormalities (WMA) are detectable on 
echocardiograms in 20% of patients [2,3,5,7]. These cardiac changes 
have been associated pulmonary edema, hypotension requiring 
vasopressor support as well as delayed cerebral ischemia (DCI), a known 
cause of death in SAH, and longer ICU stay [2,3,5,8,9,10]. It is not well 
understood how the severity of cardiac biomarkers elevation correlates 
with clinical outcomes, however. The purpose of this review is to 
identify and summarize the incidence and prognostic implications of 
elevated cardiac biomarkers on SAH outcomes.
METHODS
A search was performed on Pubmed database for the keywords 
‘aneurysmal subarachnoid hemorrhage’ AND ‘cardiomyopathy’ OR 
‘troponin’ OR ‘BNP’ OR ‘ECG’ OR ‘echocardiography’ for the time 
period of  2001 to 2021. Studies among references in articles identified 
by this search were also screened for inclusion in the systematic review. 
A study was considered eligible if it was an English language article and 
reported quantitative data cardiac biomarkers (troponin, BNP, pro-BNP), 
ECG, or echocardiogram with ejection fraction and wall motion 
abnormalities. Data were extracted about the incidence of cardiac 
complications following subarachnoid hemorrhage, qualitative 
measurement of severity of the cardiac complications (cardiac 
biomarkers, ECG, echocardiogram), clinical interventions, inpatient 
complications, and clinical outcomes.
Summary of clinical studies and reviews evaluating the prevalence of cardiac biomarkers and prognostic impact in aneurysmal SAH
Naidech, A. M., et. al.  (2005). Cardiac troponin 
elevation, cardiovascular morbidity, and outcome 
after subarachnoid hemorrhage. Circulation, 
112(18), 2851–2856. 
● cTnI reached peak around day 3 from SAH onset
● Peak cTnI was significantly associated w/ a significantly increased risk of abnormal LV wall motion on echo, pulmonary edema, hypotension treated with pressors, Delayed cerebral ischemia 
(DCI) from vasospasm, and cerebral infarction from any cause 
● Peak cTnI lvl:
○  >0.5 mcg/L → 50% risk for DCI
○  >2.0 mcg/L → 30% risk for Pulm Edema
○  >10.0 mcg/L → 40% risk for developing hypotension
● cTnI elevation was significantly associated w/ an increased likelihood of death or severe disability at discharge 
● cTnI elevation was associated w/ increased hospital stay (mean: 22.9d)
Schuiling, W. J. et. al.  (2006). ECG abnormalities in 
predicting secondary cerebral ischemia after 
subarachnoid haemorrhage. Acta neurochirurgica, 
148(8), 853–858.
● Only ST segment depression predicted the occurrence of DCI
● ST depression and ischemic ECG abnormalities (presence of ST depression or TWI, or both in at least 2 leads) appeared independent predictors of poor outcome
van der Bilt, I. A. et. al. (2009). Impact of cardiac 
complications on outcome after aneurysmal 
subarachnoid hemorrhage: a meta-analysis. 
Neurology, 72(7), 635–642. 
● Wall motion abnormalities (WMAs), elevated troponin, and proBNP lvls, tachycardia, and Q aves, ST depression, and T wave abnormalities were significantly associated w/ an increased risk 
of death
● WMAs, elevated troponin/CK-MB/proBNP lvls, ST-segment depression were significantly associated w/ an increase risk of the development of DCI
● Elevated troponin and CK-MB lvls, ST-depression were significantly associated w/ poor outcome 
Murthy, S. B. et. al.. (2015). Neurogenic Stunned 
Myocardium Following Acute Subarachnoid 
Hemorrhage: Pathophysiology and Practical 
Considerations. Journal of intensive care medicine, 
30(6), 318–325. 
● Recent studies have shown that ST-T changes and QTc prolongation have no correlation with the development of delayed cerebral ischemia, raised intracranial pressure, or mortality
● A small retrospective study observed that cTI elevation was significant associated with vasospasm and mortality, after adjusting for admission Hunt-Hess grade, age, and aneurysm size
● Patients having elevated cTI are more likely to have severe vasospasm
Akkermans, A. et. al. (2019). Cardiac events within 
one year after a subarachnoid haemorrhage: The 
predictive value of troponin elevation after 
aneurysm occlusion. European journal of preventive 
cardiology, 26(4), 420–428. 
● Troponin I elevation after occlusion of a ruptured intracranial aneurysm predicts the occurrence of a major adverse cardiac event within one year after ASAH, as measured by MACE.
Zahid, T. et. al. (2020). Cardiac Troponin Elevation 
and Outcome in Subarachnoid Hemorrhage. Cureus, 
12(8), e9792. 
● Cardiac troponin elevation post-SAH is associated w/ many systemic complications, poor outcomes and increase mortality  
● Elevated troponin and BNP predict worse outcomes after SAH
● Cardiac dysfunction defined by myocardial WMAs or positive troponin after SAH is also linked to decreased focal and global cerebral perfusion 
● WMAs are risk factor for poor clinical outcome after SAH
